MARKET
IPO

IKT

Inhibikase Therapeutics, Inc.
IKT
NASDAQ
Upcoming IPOs
Expected Listing Date: 2020-10-30
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-19.62~-16.35
83.33~100.00
-23.89~-19.90
-
Biotechnology & Medical Research
2020-07-23
Public Filing
View Prospectus
2020-10-20
Offering
Price Range: 10.00~12.00
Shares to be Issued: Pending
2020-10-29
Offering End Date
Offering Price: Pending
Post IPO Outstanding: Pending
2020-10-30
Listed
News
Financial
Releases
Corp Actions
Analysis
Profile
Inhibikase Therapeutics Starts $18 Million IPO Effort
Seeking Alpha · 07/29 04:00
U.S. IPO Weekly Recap: Software And SPACs Shine In A 7-IPO Week
Seeking Alpha · 07/25 20:22
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IKT. Analyze the recent business situations of Inhibikase Therapeutics, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IKT
Inhibikase Therapeutics Inc. is a clinical stage pharmaceutical company developing therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The Company’s lead product candidate, IkT-148009 is for the treatment of PD, and for the treatment of gastrointestinal (GI), complications that arise as early symptoms of PD in patients. The Company’s kT-148009, is a brain penetrant c-Abl protein kinase inhibitor that halts disease progression and reverses functional loss in the brain and reverses neurological dysfunction in the GI tract. The Company’s products candidate also include IKT-001Pro, which is a prodrug of the anticancer agent Imatinib, and used as a treatment for stable-phase chronic myelogenous leukemia (CML), and IKT-01427 for progressive multifocal leukoencephalopathy (PML).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Inhibikase Therapeutics, Inc. stock information, including NASDAQ:IKT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IKT stock methods without spending real money on the virtual paper trading platform.